• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL

Niel (Belgium), 1 June 2019 - eTheRNA immunotherapies NV (Niel, Belgium) announces that Dr. Ana Arance, Medical Oncologist at Hospital Clinic de Barcelona, will present safety and immune response data from the E011-MEL study at the ASCO (American Society of Clinical Oncology) Annual Meeting during the poster session “Developmental Immunotherapy and Tumor Immunobiology” on 01 June 2019. The study E011-MEL investigated the safety and immunogenicity of a mRNA-based immunotherapy ECI-006. ECI-006 is a combination of mRNAs encoding for the dendritic cell maturation triple mRNA TriMix together with mRNA coding for5 tumor-associated antigens, which aims to elicit an immune response against the tumor. Since the patients had been radically operated on, there was no expected, immediate clinical activity read-out.

The primary goal of the study was to study whether the injection of ECI-006 into inguinal or axillary lymph nodes was tolerable and clinically feasible. The intranodal injections were performed in the clinic under ultrasound guidance without anesthesia. There were two treatment arms, each of 10 patients. One group received a dose of 600 µg and the other a dose of 1800 µg per injection. The study was performed in centres in Belgium and Spain.

Appointment of Chief Financial Officer

Ulrich PlatteNiel (Belgium), 29 May 2019 - eTheRNA immunotherapies NV, the mRNA immunotherapy company, is pleased to announce the appointment of Ulrich Platte as the Company's Chief Financial Officer. Ulrich will join the company on 3rd June 2019.

Ulrich has a broad experience acquired over the last 20 years in different industries including the life sciences, medical device and pharmaceutical sectors. He has held progressively senior positions in financial management roles, including previous CFO roles, and his operational experience encompasses corporate finance, group financial control, strategic planning and M&A. Latterly Ulrich has been engaged in a number of early-stage companies in the life science sector supporting financing and business development activities. He is a graduate in business administration and holds an MBA from the University of Chicago.

Linking clinical cure of metastatic melanoma with immune responses in the TriMix DC-MEL IPI study.

Free University of Brussels (VUB), University Hospital Brussels (UZ Brussel), eTheRNA immunotherapies and HistoGeneX present new data on TriMix DC-MEL IPI study at the CIMT Annual Meeting

Niel (Belgium), 28 May 2019 - Metastatic melanoma still has very poor prognosis in spite of the addition of checkpoint inhibitors. In a study performed at the birth of immunotherapies (study started 2011) the effects of dendritic cell mRNA vaccine together with a checkpoint inhibitor (ipilimumab) showed clinical efficacy in the TriMix DC-MEL IPI study. We now have long term follow up showing 7 out of 39 patients long term disease free. The objective of the present sub-study was to retrospectively analyse patient immune cell samples, to link disease free survival with immune response.

eTheRNA Immunotherapies, VUB, UZ Brussel and HistoGeneX researchers today presented new data from the TriMixDC-MEL IPI study at the CIMT Annual Meeting. The study was performed using dendritic cells electroporated with immunostimulatory mRNA against tumor associated antigens to elicit immune attack against the tumor.

eTheRNA immunotherapies opens new research base in Ghent

Niel (Belgium), 8 May 2019 - eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies from its proprietary mRNA TriMix platform, is expanding its operation into new research laboratories this spring at the Bioscape campus in Ghent, Belgium. This new research base comes in addition to the existing manufacturing and clinical development base in Niel. The new laboratories will accommodate the company’s enlarged research and preclinical teams.